Price movement over the last 24 hours
ARK Space & Defense Innovation ETF vs Cardinal Health Inc — how do they compare? ARK Space & Defense Innovation ETF trades at $31.76, while Cardinal Health Inc trades at $236.48 (market cap $55.23B). The key difference: Cardinal Health Inc pays a 0.87% dividend while ARK Space & Defense Innovation ETF pays none, and Cardinal Health Inc is trading nearer its 52-week high, ARK Space & Defense Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKX | CAH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $37.74 | $239.71 |
52-Week Low | $24.97 | $146.04 |
Market Cap | — | $55.23B |
Enterprise Value | — | $60.20B |
Dividend Yield | — | 0.87% |
Signals from Pluang's Aura AI — not financial advice
ARK Space Exploration & Innovation ETF (ARKX) trades at $32.05, down 0.82% today amid bearish technical signals. The ETF shows neutral oscillator readings but bearish moving averages, with key support at $32 and resistance at $33. Recent news highlights ARKX as a popular alternative to direct SpaceX investment, with the space economy reaching $500 billion in backlog according to 24/7 Wall Street (2026-07-06).
ARKX offers diversified exposure to the growing space sector without single-stock IPO risk. The ETF's higher volatility and expense ratio compared to traditional aerospace ETFs present both growth potential and increased risk. SpaceX's 8.31% weighting provides significant upside exposure but also concentration risk in a high-valuation name.
Cardinal Health (CAH) trades at $235.80, up 0.87% with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with 37.08% ROE and positive revenue growth trends from $222.58B in 2025 to projected $250.7B in 2026. Recent removal from Russell indices has not dampened analyst optimism, with 54.55% maintaining buy ratings and a $248 consensus price target representing 5% upside potential.
The outlook remains positive given CAH's defensive healthcare distribution business and specialty pharma expansion. Key risks include negative shareholder equity of -$3.21B and elevated debt levels with 16.09% debt-to-asset ratio. Earnings momentum from three consecutive quarterly beats supports the bullish case, though investors should monitor the upcoming Q2 2026 results against $2.41 EPS expectations.
Trailing returns across standard periods
Latest headlines on both assets
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →